Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Regulation of Cytokines/Chemokines Release and Anti-Tumor Effect of Expanded Natural Killer (NK) Cells By a Novel Fusion of N-820 (2B8T2M), an IL-15 Superagonist with 4 Single-Chain Anti-CD20 Antibody Domains, Against Rituximab Resistant Burkitt Lymphoma (BL)

Yaya Chu, PhD, Nang Kham Su, MS, Emily K Jeng, Sarah Alter, PhD, Peter R Rhode, PhD, John H Lee, MD, Gaurav Nayyar, MD PhD, Matthew J. Barth, MD, Dean Anthony Lee, MD PhD, Hing C Wong, PhD, Mitchell Cairo, MD

Blood (2018) 132 (Supplement 1): 3697.

https://doi.org/10.1182/blood-2018-99-117683

Published: 2018

Journal Articles

First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation

Blood (2018) 131 (23): 2515–2527.

https://doi.org/10.1182/blood-2017-12-823757

Published: 2018

Includes: Supplemental data

Journal Articles

First-in-Human Clinical Trial of the IL-15 Super-Agonist Complex ALT-803 for Patients Relapsed after Allogeneic Hematopoietic Cell Transplantation

Rizwan Romee, MD, Sarah Cooley, MD, Melissa Berrien-Elliott, PhD, Peter Westervelt, MDPhD, Michael R Verneris, MD, John E. Wagner, MD, Daniel J. Weisdorf, MD, Bruce Blazar, MD, John F DiPersio, MD PhD, Amanda F. Cashen, MD, Emily K Jeng, Amy Rock, Hing C Wong, PhD, Todd A. Fehniger, MDPhD, Jeffrey S. Miller, MD

Blood (2017) 130 (Supplement 1): 274.

https://doi.org/10.1182/blood.V130.Suppl_1.274.274

Published: 2017

Journal Articles

Therapeutic Effects of a Novel Fusion of ALT-803, an IL-15 Superagonist, with 4 Single-Chains of Anti-CD20 Antibody (2B8T2M) in Combination with Expanded Natural Killer Cells Against Rituximab Sensitive and Resistant Burkitt Lymphoma (BL)

Yaya Chu, PhD, Nang Kham Su, BS, Sarah Alter, PhD, Emily K Jeng, Peter R Rhode, PhD, Matthew J. Barth, MD, Dean Anthony Lee, MD PhD, Hing C Wong, PhD, Mitchell S. Cairo, MD

Blood (2017) 130 (Supplement 1): 3587.

https://doi.org/10.1182/blood.V130.Suppl_1.3587.3587

Published: 2017

Journal Articles

The IL15 Superagonist Complex ALT-803 Potently Enhances the Proliferative Capacity and Activity of in Vitro Expanded Natural Killer Cells

Tarun K. Garg, PhD, Katie Stone, BS, Amy Greenway, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Maurizio Zangari, MD, Joshua Epstein, DSc, Brian A Walker, PhD, Hing C Wong, PhD, Emily K Jeng, Niraj Shrestha, Faith E Davies, MD, Gareth J. Morgan, MD PhD, Frits van Rhee, MD PhD

Blood (2017) 130 (Supplement 1): 5452.

https://doi.org/10.1182/blood.V130.Suppl_1.5452.5452

Published: 2017

Journal Articles

Therapeutic Effects of ALT-803, an IL-15 Superagonist, in Combination with Anti-CD20 Chimeric Antigen Receptor Modified Expanded Natural Killer CELLS Against Pediatric Burkitt Lymphoma (BL)

Yaya Chu, PhD, Fangyu Lee, Janet Ayello, MS, Brian Hang, Melanie Zhang, Hing C. Wong, Dean A Lee, MDPhD, Mitchell S. Cairo, MD

Blood (2015) 126 (23): 3085.

https://doi.org/10.1182/blood.V126.23.3085.3085

Published: 2015

Journal Articles

'First-in-human' phase I dose escalation trial of IL-15N72D/IL-15Rα-Fc superagonist complex (ALT-803) demonstrates immune activation with anti-tumor activity in patients with relapsed hematological malignancy

Jeffrey S. Miller, MD, Sarah Cooley, MD, Shernan Holtan, Mukta Arora, MD, Celalettin Ustun, MD, Emily Jeng, Hing C. Wong, Michael R. Verneris, MD, John E. Wagner, MD, Daniel J. Weisdorf, MD, Bruce R. Blazar, MD, Todd A Fehniger, MD PhD, Rizwan Romee, MD

Blood (2015) 126 (23): 1957.

https://doi.org/10.1182/blood.V126.23.1957.1957

Published: 2015

NARROW

Regulation of Cytokines/Chemokines Release and Anti-Tumor Effect of Expanded Natural Killer (NK) Cells By a Novel Fusion of N-820 (2B8T2M), an IL-15 Superagonist with 4 Single-Chain Anti-CD20 Antibody Domains, Against Rituximab Resistant Burkitt Lymphoma (BL)

First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation

First-in-Human Clinical Trial of the IL-15 Super-Agonist Complex ALT-803 for Patients Relapsed after Allogeneic Hematopoietic Cell Transplantation

Therapeutic Effects of a Novel Fusion of ALT-803, an IL-15 Superagonist, with 4 Single-Chains of Anti-CD20 Antibody (2B8T2M) in Combination with Expanded Natural Killer Cells Against Rituximab Sensitive and Resistant Burkitt Lymphoma (BL)

The IL15 Superagonist Complex ALT-803 Potently Enhances the Proliferative Capacity and Activity of in Vitro Expanded Natural Killer Cells

Therapeutic Effects of ALT-803, an IL-15 Superagonist, in Combination with Anti-CD20 Chimeric Antigen Receptor Modified Expanded Natural Killer CELLS Against Pediatric Burkitt Lymphoma (BL)

'First-in-human' phase I dose escalation trial of IL-15N72D/IL-15Rα-Fc superagonist complex (ALT-803) demonstrates immune activation with anti-tumor activity in patients with relapsed hematological malignancy

Email alerts

ASH Publications

American Society of Hematology

Regulation of Cytokines/Chemokines Release and Anti-Tumor Effect of Expanded Natural Killer (NK) Cells By a Novel Fusion of N-820 (2B8T2M), an IL-15 Superagonist with 4 Single-Chain Anti-CD20 Antibody Domains, Against Rituximab Resistant Burkitt Lymphoma (BL)

First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation

First-in-Human Clinical Trial of the IL-15 Super-Agonist Complex ALT-803 for Patients Relapsed after Allogeneic Hematopoietic Cell Transplantation

Therapeutic Effects of a Novel Fusion of ALT-803, an IL-15 Superagonist, with 4 Single-Chains of Anti-CD20 Antibody (2B8T2M) in Combination with Expanded Natural Killer Cells Against Rituximab Sensitive and Resistant Burkitt Lymphoma (BL)

The IL15 Superagonist Complex ALT-803 Potently Enhances the Proliferative Capacity and Activity of in Vitro Expanded Natural Killer Cells

Therapeutic Effects of ALT-803, an IL-15 Superagonist, in Combination with Anti-CD20 Chimeric Antigen Receptor Modified Expanded Natural Killer CELLS Against Pediatric Burkitt Lymphoma (BL)

'First-in-human' phase I dose escalation trial of IL-15N72D/IL-15Rα-Fc superagonist complex (ALT-803) demonstrates immune activation with anti-tumor activity in patients with relapsed hematological malignancy

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only